Lymphocyte subset panels: diagnostic pathways for recurrent infections

A peripheral-blood flow-cytometry panel does not identify every primary immunodeficiency. It provides a quantitative map of circulating T cells, B cells, and natural killer cells that can narrow the diagnostic pathway.

The core assay measures CD3, CD4, CD8, CD19 or CD20, and CD16 or CD56. Results are reported as both absolute counts, expressed as cells per microliter, and percentages of circulating lymphocytes. These two outputs are not interchangeable. A normal percentage can coexist with a clinically significant reduction in absolute cells, particularly when the total lymphocyte count is abnormal.

Clinical indicators: anatomical defects versus systemic immunodeficiency

Recurrent infection is not a sufficient indication for indiscriminate immune testing. The anatomical distribution of infection changes the pretest probability.

Repeated infections confined to one anatomical site are more compatible with a local structural problem. Examples include recurrent disease associated with a single airway segment, a persistent drainage site, a urinary tract abnormality, or another defined anatomical region. In this pattern, local imaging, structural assessment, microbiological evaluation, or specialist examination may have higher initial diagnostic yield than lymphocyte phenotyping.

Infections affecting two or more distinct anatomical sites raise greater suspicion for a systemic immune disorder. The concern increases further when infections are severe, persistent, unusually difficult to treat, or caused by organisms that are not typical for the child’s age and clinical setting.

The panel is most useful when the clinical phenotype supports a defect in lymphocyte number or distribution. It is less informative when recurrent symptoms are better explained by exposure frequency, incomplete recovery between infections, chronic inflammation, aspiration, anatomical disease, or a localized defect.

A practical clinical assessment separates the following variables:

• Distribution: one anatomical site versus multiple independent sites.
• Severity: outpatient infections versus invasive, prolonged, or treatment-resistant disease.
• Persistence: complete resolution between episodes versus continuous or relapsing symptoms.
• Pathogen profile: expected community pathogens versus opportunistic or unusually severe infections.
• Hematology: total lymphocyte count, neutrophil count, hemoglobin, and platelet abnormalities.
• Growth and systemic findings: poor growth, chronic diarrhea, persistent mucosal disease, or other signs of multisystem involvement.
• Treatment response: expected recovery with standard therapy versus delayed or incomplete response.

The diagnostic pathway should therefore begin with the phenotype, not with the assay menu. A flow-cytometric panel ordered without a defined clinical question can produce an abnormal result that is difficult to interpret and may not alter management.

A lymphocyte subset panel is a cell-distribution assay. It is not a standalone diagnosis of genetic immunodeficiency.

The mechanics of lymphocyte phenotyping

Flow cytometry uses fluorescently labeled antibodies to identify cell populations according to surface-marker expression. In pediatric immunology, the standard lymphocyte subset panel focuses on three major compartments: T lymphocytes, B lymphocytes, and natural killer cells.

T-cell markers

CD3 identifies mature T lymphocytes. Within the CD3-positive population, CD4 and CD8 separate major functional subsets:

• CD3: total mature T-cell population.
• CD4: helper T-cell compartment.
• CD8: cytotoxic T-cell compartment.

The CD4 and CD8 results are usually interpreted as both absolute counts and percentages. The relationship between the two populations may also be clinically relevant, but no single ratio should be interpreted without age-specific laboratory context and the rest of the immune evaluation.

A marked reduction in circulating T cells can support concern for a severe cellular immunodeficiency, including a phenotype compatible with severe combined immunodeficiency. However, flow cytometry measures circulating cells. It does not establish whether those cells are functionally competent, whether they proliferate appropriately, or whether they contain a specific pathogenic variant.

B-cell markers

CD19 and CD20 identify the principal circulating B-cell compartment. Depending on the assay design, one or both markers may be used for B-cell enumeration.

A reduced B-cell population can narrow the differential diagnosis toward disorders affecting B-cell development or maturation. A preserved B-cell count does not establish normal antibody production. B-cell number and B-cell function are separate diagnostic variables. Quantitative immunoglobulins, vaccine-specific antibody responses, and additional molecular or functional studies may be required.

Natural killer cell markers

CD16 and CD56 identify the principal natural killer cell population in a standard lymphocyte subset panel. Natural killer cells are reported as a percentage and an absolute count, just like T and B cells.

An abnormal NK-cell result can be relevant in selected immune disorders, but interpretation depends on the broader phenotype. The standard CD16/CD56 measurement is a quantitative screening assessment. It does not fully characterize NK-cell cytotoxic function or every maturation state.

What the panel actually reports

A typical report may include the following structure:

The output is quantitative, but it is not self-interpreting. A value outside the local laboratory range may reflect age, acute illness, recent treatment, specimen quality, or a true immunological abnormality.

When to order lymphocyte subset testing

The question is not whether recurrent infection is present. The relevant question is whether the observed infection pattern warrants a cell-distribution assay as part of a broader primary immunodeficiency evaluation.

Lymphocyte subset testing has higher clinical value when:

1. Infections involve multiple anatomical sites.

A pattern extending beyond one local structure is more consistent with a systemic process than with an isolated anatomical defect.

2. The illness is severe or unusually persistent.

Prolonged infection, repeated hospitalization, invasive disease, or poor response to standard treatment increases the value of immunological investigation.

3. The complete blood count suggests lymphopenia.

Flow cytometry can define which lymphocyte compartments are reduced. The result is more useful when interpreted alongside the total white-cell and lymphocyte counts.

4. The clinical phenotype suggests T-cell dysfunction.

Persistent viral, fungal, or opportunistic infections may justify evaluation of the T-cell compartment, although the panel cannot replace functional testing.

5. There is concern about combined immunodeficiency.

Measurement of T, B, and NK cells provides an initial cellular profile and can help determine the urgency and direction of subsequent testing.

6. A broader immunodeficiency evaluation has already identified a relevant abnormality.

The panel can refine the phenotype and support selection of functional or genetic assays.

Testing has lower first-line utility when infections are recurrent but anatomically localized, mild, clearly exposure-related, or associated with a structural explanation. This does not exclude immune disease. It changes the order of investigations.

Absolute count versus percentage

The interpretation of pediatric flow cytometry reports frequently fails at this point. Percentages describe the composition of the lymphocyte pool. Absolute counts describe the number of cells in a unit volume of blood.

If total lymphocytes are reduced, a subset can retain a seemingly ordinary percentage while the absolute count is clinically low. Conversely, a high percentage may result from a reduction in another lymphocyte compartment rather than an expansion of the measured population.

A report should therefore be reviewed in this sequence:

• Confirm the child’s age and the laboratory’s pediatric reference interval.
• Review the total white-cell and absolute lymphocyte counts.
• Examine absolute CD3, CD4, CD8, CD19/CD20, and CD16/CD56 values.
• Compare the corresponding percentages.
• Check whether the sample was collected during acute infection or after immune-modulating treatment.
• Assess whether the abnormality affects one compartment or several.
• Determine whether repeat testing or confirmatory studies are required.

There is no universal reference range that can be applied across all pediatric age groups. Lymphocyte distributions change substantially during childhood. Regional laboratory methods and reference populations also differ. The report’s own age-specific interval has priority over an adult range or a value copied from an unrelated laboratory.

Diagnostic pathways from screening to functional assays

Flow cytometry is usually one component in a sequence rather than the endpoint. The order of testing should follow the cellular phenotype and the suspected mechanism.

Pathway 1: preserved major lymphocyte compartments

A child may have recurrent infections with normal absolute T-cell, B-cell, and NK-cell counts. This result reduces the likelihood of a major quantitative lymphocyte deficiency, but it does not exclude immune dysfunction.

The next diagnostic layer may include:

• quantitative immunoglobulin assessment;
• evaluation of specific antibody responses;
• review of vaccine-response data;
• complement testing when clinically indicated;
• neutrophil number and function assessment;
• targeted functional assays based on the infection phenotype;
• molecular testing when the phenotype remains concerning.

A normal subset panel cannot exclude antibody deficiency, innate immune defects, phagocyte dysfunction, or disorders in which cell number is preserved but cell function is impaired.

Pathway 2: reduced T-cell compartment

A low CD3 count, particularly when accompanied by reduced CD4 and/or CD8 populations, requires confirmation and clinical correlation. The result may support concern for a T-cell or combined immunodeficiency, but it is not sufficient to assign a genetic diagnosis.

The subsequent evaluation can include functional T-cell assays, depending on the clinical question. Delayed hypersensitivity skin testing with antigens such as Candida, mumps, or tetanus may be used in children older than one year to assess cellular immune responsiveness. This approach is not a replacement for molecular testing and is not applicable in every clinical situation.

Age, acute infection, nutritional state, treatment exposure, and specimen quality can affect the result. A severe reduction should be treated as a clinically significant finding requiring prompt specialist interpretation, while a borderline result may require repeat measurement under more stable conditions.

Pathway 3: reduced or absent B-cell compartment

A low CD19/CD20 population redirects the evaluation toward B-cell development and antibody production. Quantitative immunoglobulins and vaccine-specific antibody responses become particularly relevant.

A normal B-cell count does not guarantee adequate antibody function. Conversely, a low B-cell count must be interpreted with the clinical history and other laboratory data. The diagnostic objective is not simply to label the cell count as low. It is to determine whether the finding corresponds to a reproducible defect in B-cell development, maturation, or antibody production.

Pathway 4: abnormal NK-cell compartment

An abnormal CD16/CD56 result can support further investigation when the phenotype includes severe or unusual viral infections, persistent disease, or other findings compatible with NK-cell dysfunction. Quantitative enumeration alone does not measure cytotoxic capacity. Functional NK-cell testing may therefore be required.

Pathway 5: multiple abnormal compartments

Concurrent abnormalities in T, B, and NK cells increase concern for a broader lymphocyte-development defect or a severe combined phenotype. The interpretation remains dependent on absolute counts, age, clinical severity, and repeatability.

In this setting, diagnostic delay has greater clinical cost than in a low-risk recurrent-infection pattern. The panel may be followed by urgent functional and molecular testing, with clinical management proceeding in parallel rather than waiting for a complete genetic classification.

Technical requirements for accurate pediatric immunophenotyping

Pre-analytical variables directly affect flow-cytometry accuracy. Pediatric specimens are often limited in volume, making collection and transport discipline essential.

A standard lymphocyte subset panel generally uses approximately 4 mL of whole blood. The minimum accepted sample volume may be 0.5 mL, depending on the laboratory and the assay configuration. Acceptable collection tubes include:

• lavender EDTA tubes;
• pink K2EDTA tubes;
• green sodium-heparin or lithium-heparin tubes.

The laboratory’s collection requirements take precedence because tube type, minimum volume, transport window, and specimen stability can vary by platform.

The following factors can degrade interpretability:

• insufficient sample volume;
• incorrect anticoagulant;
• delayed transport;
• temperature exposure outside laboratory specifications;
• clotting or hemolysis;
• severe leukopenia;
• processing after substantial cellular deterioration;
• inadequate clinical information on the requisition.

The requisition should identify the child’s age, relevant infection pattern, current treatment, recent transfusion history when applicable, and the clinical question. A report that lacks this context can still be technically valid but less clinically actionable.

Why specimen stability matters

Flow cytometry depends on intact cells and reliable antigen expression. Poorly preserved specimens can produce weak signals, reduced event recovery, or an unreliable separation between cell populations. This is particularly consequential when the expected abnormality is subtle.

The assay should therefore be viewed as a chain:

1. appropriate clinical indication;

2. correct blood collection;

3. controlled transport;

4. validated antibody panel;

5. adequate event acquisition;

6. age-adjusted interpretation;

7. confirmatory testing when indicated.

Failure at any step can reduce diagnostic yield. The instrument’s output does not compensate for a compromised specimen.

Interpreting abnormal results without overcalling disease

An abnormal lymphocyte subset result is a finding, not an etiological conclusion. Several mechanisms can produce transient or secondary changes in circulating lymphocyte populations.

The report should be assessed for internal coherence. For example, a low percentage accompanied by a normal absolute count may not represent true depletion. A low absolute count with a preserved percentage may reflect global lymphopenia. A discrepancy between the automated complete blood count and flow-cytometry estimate should trigger technical and clinical review rather than immediate diagnostic labeling.

A useful interpretation separates three questions:

Is the abnormality real?

The result should be compared with the complete blood count, clinical state, specimen quality, and prior measurements. A single abnormal result may require confirmation, particularly when the abnormality is mild and the child is acutely ill.

Is the abnormality clinically relevant?

The magnitude, affected compartment, infection phenotype, and associated laboratory findings determine relevance. A small isolated deviation in an otherwise well child does not carry the same weight as profound multi-lineage lymphopenia in a child with invasive infections.

Does the abnormality explain the phenotype?

A reduced cell count can support a mechanistic hypothesis, but the relationship must be biologically and clinically plausible. A normal T-cell count does not explain away recurrent infections, and a low NK-cell percentage does not by itself establish NK-cell disease.

The assay’s specificity is therefore conditional. Specificity improves when the pretest phenotype is well defined, the specimen is reliable, and the result is consistent with complementary testing. It decreases when testing is performed in a low-risk population or interpreted without age-adjusted standards.

The useful result is not the most abnormal number. It is the result that changes the next diagnostic decision.

Beyond the panel: molecular testing and genetic sequencing

Lymphocyte phenotyping defines the cellular architecture of the circulating immune system. Molecular diagnostics addresses the genetic mechanism. These functions are complementary.

Genetic testing becomes more relevant when:

• the phenotype is severe or highly characteristic;
• the subset pattern suggests a defined developmental defect;
• there is a family history of primary immunodeficiency;
• multiple relatives show compatible disease;
• functional assays support a specific pathway abnormality;
• the clinical presentation remains unexplained after standard immunological testing.

The choice between a targeted panel, broader sequencing, or another molecular strategy depends on the phenotype and laboratory practice. Targeted testing can be efficient when the clinical and cellular pattern strongly supports a limited group of genes. Broader sequencing may be considered when the phenotype is heterogeneous, atypical, or not explained by initial testing.

A pathogenic variant must still be interpreted in clinical context. Detection of a variant does not automatically prove causality. Classification requires consideration of inheritance, population frequency, functional evidence, phenotype concordance, and the laboratory’s interpretation framework.

Conversely, a negative genetic panel does not exclude immune disease. Technical coverage, variant type, regulatory regions, structural variation, newly recognized disease genes, and non-genetic causes all limit the sensitivity of molecular testing.

Newborn screening and later diagnostic evaluation

Newborn screening for severe combined immunodeficiency uses a different biological signal from a later lymphocyte subset panel. Screening is designed to identify infants at risk through an early population-level method. Flow cytometry in a symptomatic child is a diagnostic assay that quantifies defined circulating cell populations.

The two approaches should not be treated as interchangeable. A positive newborn screen requires diagnostic confirmation. A normal screen does not eliminate every form of childhood immunodeficiency, particularly disorders that present later or primarily affect antibody function, innate immunity, or lymphocyte function rather than early T-cell production.

Clinical utility of the panel

The clinical utility of lymphocyte subset testing is highest when it answers a specific question:

• Is there a quantitative deficiency in T cells, B cells, or NK cells?
• Is the pattern compatible with a severe combined phenotype?
• Should functional immune assays be prioritized?
• Does the result support urgent molecular testing?
• Is the observed infection burden better explained by a non-immune process?

The panel is not a universal screening test for every child with frequent infections. It has limited value when the infection pattern is localized and a structural explanation is more probable. It also has limited value as a standalone exclusion test: normal counts do not exclude functional immune defects.

For parents, the key interpretation issue is that a report containing several percentages is not equivalent to a diagnosis. For clinicians, the key operational issue is that the request should specify the clinical indication and the laboratory should provide pediatric reference intervals. For laboratories, analytical quality depends on specimen integrity, validated gating strategy, adequate event acquisition, and clear reporting of absolute counts alongside percentages.

The diagnostic pathway is therefore sequential:

1. define the infection phenotype;

2. distinguish localized disease from systemic suspicion;

3. review the complete blood count and absolute lymphocyte count;

4. perform lymphocyte subset phenotyping when clinically indicated;

5. interpret age-adjusted absolute counts and percentages together;

6. confirm persistent or high-risk abnormalities;

7. add functional assays, immunoglobulin testing, or molecular diagnostics according to the cellular pattern.

The rigid clinical assessment is straightforward. Lymphocyte subset panels provide high-value quantitative information about circulating immune-cell compartments. They can identify patterns compatible with T-cell, B-cell, NK-cell, or combined abnormalities. They cannot independently establish genetic causation, cellular function, or the complete absence of immunodeficiency. Their diagnostic accuracy depends on correct patient selection, specimen handling, pediatric reference data, and integration with complementary assays.